AI assistant
GENETIC TECHNOLOGIES LIMITED — Share Issue/Capital Change 2019
Mar 11, 2019
65022_rns_2019-03-11_fe63826a-8336-42c3-937b-867caf0c8ae1.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
==> picture [595 x 68] intentionally omitted <==
==> picture [595 x 68] intentionally omitted <==
ASX ANNOUNCEMENT 12 March 2019
Lapse of Employee Share Options
Melbourne, Australia, 12 March 2019: Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “ Company ”), advises that 15,000,000 unlisted share options granted pursuant to the Company’s employee option plan have lapsed. The details of these lapsed options are:
| Unlisted employee option reference |
Exercise price | Options lapsed |
|---|---|---|
| GTGAD (expiring24 November 2020) |
$0.020 | 15,000,000 |
| Total | 15,000,000 |
Accordingly, as at the date of this announcement, there are a total of 54,366,667 outstanding options over shares in the Company.
About Genetic Technologies Limited
Genetic Technologies is a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead product, BREVAGen plus[®] , is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. For more information, please visit www.brevagenplus.com and www.phenogensciences.com.
Genetic Technologies is developing a pipeline of risk assessment products including a novel colorectal cancer (CRC) test. For more information, please visit www.gtgcorporate.com
Safe Harbor Statement
Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.
FOR FURTHER INFORMATION PLEASE CONTACT
Mr Paul Viney Company Secretary Genetic Technologies Limited +61438072616
Genetic Technologies Limited • Website : www.gtglabs.com • Email : [email protected] ABN 17 009 212 328 Registered Office • 60-66 Hanover Street Fitzroy Victoria 3065 Australia • Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia Phone +61 3 8412 7000 • Fax +61 3 8412 7040